H.C. Wainwright sees FDA Priority Review as positive signal for Agios' mitapivat
H.C. Wainwright analyst Emily Bodnar notes that Agios Pharmaceuticals announced that the FDA accepted its sNDA for mitapivat, in sickle cell disease under the accelerated approval pathway with a Priority Review and a PDUFA goal date of November 1, 2026. The firm views the Priority Review as a positive regulatory signal